Biopharma AI
By
How Did Roche’s 2025 Deals Shape Its Strategy and Future Outlook?
In 2025, Roche executed a series of focused deals and collaborations designed to strengthen its scientific platforms, expand…
How Did Roche Navigate 2025 and What Lies Ahead for 2026?
Roche concluded 2025 as a company demonstrating resilient performance, strategic focus, and continued innovation across its pharmaceuticals and…
How Did Johnson & Johnson’s 2025 Deals Shape Its Strategy, and What Do They Signal for 2026?
New Brunswick, NJ — In 2025, Johnson & Johnson executed a series of strategic collaborations, acquisitions, and partnerships…
How Did Johnson & Johnson Navigate 2025 and What Lies Ahead for 2026?
Johnson & Johnson concluded 2025 with a combination of resilient portfolio performance, strategic execution, and ongoing innovation across…
Is AI Becoming Big Pharma’s Frontline Tool for Early Cancer Detection? Bristol Myers Squibb and Microsoft Signal a Strategic Shift
Executive Summary Bristol Myers Squibb (BMS) has entered a strategic partnership with Microsoft to advance AI-driven early detection…
How Will Hippocratic AI Leverage Grove AI to Accelerate Trial Efficiency and Patient Engagement?
January 22, 2026 — Global — BioNexAI Market Insights reports that Hippocratic AI, a leading AI innovator, has…
